Healthcare firm Omega Diagnostics has told investors that it is in a stronger position following an “extremely challenging year” which led to the disposal of its Clackmannanshire facility.
Releasing full-year results, the group said the past 12 months had been dominated by a Covid-19 opportunity that “ultimately did not come to fruition” and which destabilised the whole business.
At the start of last month, Omega sold its CD4 testing business to the same Chinese-owned firm that bought its Clackmannanshire manufacturing facility earlier this year.
The group confirmed that it had completed the disposal of the loss-making CD4 operation to Accubio, a wholly-owned subsidiary of Zhejiang Orient Gene Biotech, for a total cash consideration of up to £6.1 million, before costs.
